6 O
ADVERSE O
REACTIONS O
EXCERPT O
: O
The O
most O
commonly O
reported O
adverse O
reactions O
during O
the O
first O
3 O
months O
in O
controlled O
clinical O
trials O
( O
occurring O
in O
greater O
than O
or O
equal O
to O
2 O
% O
of O
patients O
treated O
with O
XELJANZ O
monotherapy O
or O
in O
combination O
with O
DMARDs O
) O
were O
upper O
respiratory O
tract O
infections O
, O
headache O
, O
diarrhea O
and O
nasopharyngitis O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Pfizer O
, O
Inc O
at O
1-800-438-1985 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trial O
Experience O
Because O
clinical O
studies O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
studies O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
studies O
of O
another O
drug O
and O
may O
not O
predict O
the O
rates O
observed O
in O
a O
broader O
patient O
population O
in O
clinical O
practice O
. O

Although O
other O
doses O
have O
been O
studied O
, O
the O
recommended O
dose O
of O
XELJANZ O
is O
5 O
mg O
twice O
daily O
. O

The O
following O
data O
includes O
two O
Phase O
2 O
and O
five O
Phase O
3 O
double-blind O
, O
controlled O
, O
multicenter O
trials O
. O

In O
these O
trials O
, O
patients O
were O
randomized O
to O
doses O
of O
XELJANZ O
5 O
mg O
twice O
daily O
( O
292 O
patients O
) O
and O
10 O
mg O
twice O
daily O
( O
306 O
patients O
) O
monotherapy O
, O
XELJANZ O
5 O
mg O
twice O
daily O
( O
1044 O
patients O
) O
and O
10 O
mg O
twice O
daily O
( O
1043 O
patients O
) O
in O
combination O
with O
DMARDs O
( O
including O
methotrexate O
) O
and O
placebo O
( O
809 O
patients O
) O
. O

All O
seven O
protocols O
included O
provisions O
for O
patients O
taking O
placebo O
to O
receive O
treatment O
with O
XELJANZ O
at O
Month O
3 O
or O
Month O
6 O
either O
by O
patient O
response O
( O
based O
on O
uncontrolled O
disease O
activity O
) O
or O
by O
design O
, O
so O
that O
adverse O
events O
can O
not O
always O
be O
unambiguously O
attributed O
to O
a O
given O
treatment O
. O

Therefore O
some O
analyses O
that O
follow O
include O
patients O
who O
changed O
treatment O
by O
design O
or O
by O
patient O
response O
from O
placebo O
to O
XELJANZ O
in O
both O
the O
placebo O
and O
XELJANZ O
group O
of O
a O
given O
interval O
. O

Comparisons O
between O
placebo O
and O
XELJANZ O
were O
based O
on O
the O
first O
3 O
months O
of O
exposure O
, O
and O
comparisons O
between O
XELJANZ O
5 O
mg O
twice O
daily O
and O
XELJANZ O
10 O
mg O
twice O
daily O
were O
based O
on O
the O
first O
12 O
months O
of O
exposure O
. O

The O
long-term O
safety O
population O
includes O
all O
patients O
who O
participated O
in O
a O
double-blind O
, O
controlled O
trial O
( O
including O
earlier O
development O
phase O
studies O
) O
and O
then O
participated O
in O
one O
of O
two O
long-term O
safety O
studies O
. O

The O
design O
of O
the O
long-term O
safety O
studies O
allowed O
for O
modification O
of O
XELJANZ O
doses O
according O
to O
clinical O
judgment O
. O

This O
limits O
the O
interpretation O
of O
the O
long-term O
safety O
data O
with O
respect O
to O
dose O
. O

The O
most O
common O
serious O
adverse O
reactions O
were O
serious O
infections B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

The O
proportion O
of O
patients O
who O
discontinued O
treatment O
due O
to O
any O
adverse O
reaction O
during O
the O
0 O
to O
3 O
months O
exposure O
in O
the O
double-blind O
, O
placebo-controlled O
trials O
was O
4 O
% O
for O
patients O
taking O
XELJANZ O
and O
3 O
% O
for O
placebo-treated O
patients O
. O

Overall O
Infections O
In O
the O
seven O
controlled O
trials O
, O
during O
the O
0 O
to O
3 O
months O
exposure O
, O
the O
overall O
frequency O
of O
infections B-OSE_Labeled_AE
was O
20 O
% O
and O
22 O
% O
in O
the O
5 O
mg O
twice O
daily O
and O
10 O
mg O
twice O
daily O
groups O
, O
respectively O
, O
and O
18 O
% O
in O
the O
placebo O
group O
. O

The O
most O
commonly O
reported O
infections B-OSE_Labeled_AE
with O
XELJANZ O
were O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
, O
nasopharyngitis B-OSE_Labeled_AE
, O
and O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
( O
4 O
% O
, O
3 O
% O
, O
and O
2 O
% O
of O
patients O
, O
respectively O
) O
. O

Serious O
Infections O
In O
the O
seven O
controlled O
trials O
, O
during O
the O
0 O
to O
3 O
months O
exposure O
, O
serious O
infections B-OSE_Labeled_AE
were O
reported O
in O
1 O
patient O
( O
0.5 O
events O
per O
100 O
patient-years O
) O
who O
received O
placebo O
and O
11 O
patients O
( O
1.7 O
events O
per O
100 O
patient-years O
) O
who O
received O
XELJANZ O
5 O
mg O
or O
10 O
mg O
twice O
daily O
. O

The O
rate O
difference O
between O
treatment O
groups O
( O
and O
the O
corresponding O
95 O
% O
confidence O
interval O
) O
was O
1.1 O
( O
-0.4 O
, O
2.5 O
) O
events O
per O
100 O
patient-years O
for O
the O
combined O
5 O
mg O
twice O
daily O
and O
10 O
mg O
twice O
daily O
XELJANZ O
group O
minus O
placebo O
. O

In O
the O
seven O
controlled O
trials O
, O
during O
the O
0 O
to O
12 O
months O
exposure O
, O
serious O
infections B-OSE_Labeled_AE
were O
reported O
in O
34 O
patients O
( O
2.7 O
events O
per O
100 O
patient-years O
) O
who O
received O
5 O
mg O
twice O
daily O
of O
XELJANZ O
and O
33 O
patients O
( O
2.7 O
events O
per O
100 O
patient-years O
) O
who O
received O
10 O
mg O
twice O
daily O
of O
XELJANZ O
. O

The O
rate O
difference O
between O
XELJANZ O
doses O
( O
and O
the O
corresponding O
95 O
% O
confidence O
interval O
) O
was O
-0.1 O
( O
-1.3 O
, O
1.2 O
) O
events O
per O
100 O
patient-years O
for O
10 O
mg O
twice O
daily O
XELJANZ O
minus O
5 O
mg O
twice O
daily O
XELJANZ O
. O

The O
most O
common O
serious O
infections B-OSE_Labeled_AE
included O
pneumonia B-OSE_Labeled_AE
, O
cellulitis B-OSE_Labeled_AE
, O
herpes B-OSE_Labeled_AE
zoster I-OSE_Labeled_AE
, O
and O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

Tuberculosis O
In O
the O
seven O
controlled O
trials O
, O
during O
the O
0 O
to O
3 O
months O
exposure O
, O
tuberculosis B-NonOSE_AE
was O
not O
reported O
in O
patients O
who O
received O
placebo O
, O
5 O
mg O
twice O
daily O
of O
XELJANZ O
, O
or O
10 O
mg O
twice O
daily O
of O
XELJANZ O
. O

In O
the O
seven O
controlled O
trials O
, O
during O
the O
0 O
to O
12 O
months O
exposure O
, O
tuberculosis B-OSE_Labeled_AE
was O
reported O
in O
0 O
patients O
who O
received O
5 O
mg O
twice O
daily O
of O
XELJANZ O
and O
6 O
patients O
( O
0.5 O
events O
per O
100 O
patient-years O
) O
who O
received O
10 O
mg O
twice O
daily O
of O
XELJANZ O
. O

The O
rate O
difference O
between O
XELJANZ O
doses O
( O
and O
the O
corresponding O
95 O
% O
confidence O
interval O
) O
was O
0.5 O
( O
0.1 O
, O
0.9 O
) O
events O
per O
100 O
patient-years O
for O
10 O
mg O
twice O
daily O
XELJANZ O
minus O
5 O
mg O
twice O
daily O
XELJANZ O
. O

Cases O
of O
disseminated B-OSE_Labeled_AE
tuberculosis I-OSE_Labeled_AE
were O
also O
reported O
. O

The O
median O
XELJANZ O
exposure O
prior O
to O
diagnosis O
of O
tuberculosis B-OSE_Labeled_AE
was O
10 O
months O
( O
range O
from O
152 O
to O
960 O
days O
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

Opportunistic O
Infections O
( O
excluding O
tuberculosis O
) O
In O
the O
seven O
controlled O
trials O
, O
during O
the O
0 O
to O
3 O
months O
exposure O
, O
opportunistic B-NonOSE_AE
infections I-NonOSE_AE
were O
not O
reported O
in O
patients O
who O
received O
placebo O
, O
5 O
mg O
twice O
daily O
of O
XELJANZ O
, O
or O
10 O
mg O
twice O
daily O
of O
XELJANZ O
. O

In O
the O
seven O
controlled O
trials O
, O
during O
the O
0 O
to O
12 O
months O
exposure O
, O
opportunistic B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
were O
reported O
in O
4 O
patients O
( O
0.3 O
events O
per O
100 O
patient-years O
) O
who O
received O
5 O
mg O
twice O
daily O
of O
XELJANZ O
and O
4 O
patients O
( O
0.3 O
events O
per O
100 O
patient-years O
) O
who O
received O
10 O
mg O
twice O
daily O
of O
XELJANZ O
. O

The O
rate O
difference O
between O
XELJANZ O
doses O
( O
and O
the O
corresponding O
95 O
% O
confidence O
interval O
) O
was O
0 O
( O
-0.5 O
, O
0.5 O
) O
events O
per O
100 O
patient-years O
for O
10 O
mg O
twice O
daily O
XELJANZ O
minus O
5 O
mg O
twice O
daily O
XELJANZ O
. O

The O
median O
XELJANZ O
exposure O
prior O
to O
diagnosis O
of O
an O
opportunistic B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
was O
8 O
months O
( O
range O
from O
41 O
to O
698 O
days O
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

Malignancy O
In O
the O
seven O
controlled O
trials O
, O
during O
the O
0 O
to O
3 O
months O
exposure O
, O
malignancies B-OSE_Labeled_AE
excluding O
NMSC B-NonOSE_AE
were O
reported O
in O
0 O
patients O
who O
received O
placebo O
and O
2 O
patients O
( O
0.3 O
events O
per O
100 O
patient-years O
) O
who O
received O
either O
XELJANZ O
5 O
mg O
or O
10 O
mg O
twice O
daily O
. O

The O
rate O
difference O
between O
treatment O
groups O
( O
and O
the O
corresponding O
95 O
% O
confidence O
interval O
) O
was O
0.3 O
( O
-0.1 O
, O
0.7 O
) O
events O
per O
100 O
patient-years O
for O
the O
combined O
5 O
mg O
and O
10 O
mg O
twice O
daily O
XELJANZ O
group O
minus O
placebo O
. O

In O
the O
seven O
controlled O
trials O
, O
during O
the O
0 O
to O
12 O
months O
exposure O
, O
malignancies B-OSE_Labeled_AE
excluding O
NMSC B-NonOSE_AE
were O
reported O
in O
5 O
patients O
( O
0.4 O
events O
per O
100 O
patient-years O
) O
who O
received O
5 O
mg O
twice O
daily O
of O
XELJANZ O
and O
7 O
patients O
( O
0.6 O
events O
per O
100 O
patient-years O
) O
who O
received O
10 O
mg O
twice O
daily O
of O
XELJANZ O
. O

The O
rate O
difference O
between O
XELJANZ O
doses O
( O
and O
the O
corresponding O
95 O
% O
confidence O
interval O
) O
was O
0.2 O
( O
-0.4 O
, O
0.7 O
) O
events O
per O
100 O
patient-years O
for O
10 O
mg O
twice O
daily O
XELJANZ O
minus O
5 O
mg O
twice O
daily O
XELJANZ O
. O

One O
of O
these O
malignancies B-OSE_Labeled_AE
was O
a O
case O
of O
lymphoma B-OSE_Labeled_AE
that O
occurred O
during O
the O
0 O
to O
12 O
month O
period O
in O
a O
patient O
treated O
with O
XELJANZ O
10 O
mg O
twice O
daily O
. O

The O
most O
common O
types O
of O
malignancy B-OSE_Labeled_AE
, O
including O
malignancies B-OSE_Labeled_AE
observed O
during O
the O
long-term O
extension O
, O
were O
lung B-OSE_Labeled_AE
and O
breast O
cancer I-OSE_Labeled_AE
, O
followed O
by O
gastric B-OSE_Labeled_AE
, O
colorectal O
, O
renal O
cell O
, O
prostate O
cancer I-OSE_Labeled_AE
, O
lymphoma B-OSE_Labeled_AE
, O
and O
malignant B-OSE_Labeled_AE
melanoma I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

Laboratory O
Abnormalities O
Lymphopenia B-OSE_Labeled_AE
In O
the O
controlled O
clinical O
trials O
, O
confirmed O
decreases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
absolute I-OSE_Labeled_AE
lymphocyte I-OSE_Labeled_AE
counts I-OSE_Labeled_AE
below O
500 O
cells/mm O
3 O
occurred O
in O
0.04 O
% O
of O
patients O
for O
the O
5 O
mg O
twice O
daily O
and O
10 O
mg O
twice O
daily O
XELJANZ O
groups O
combined O
during O
the O
first O
3 O
months O
of O
exposure O
. O

Confirmed O
lymphocyte B-OSE_Labeled_AE
counts I-OSE_Labeled_AE
less I-OSE_Labeled_AE
than I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
cells I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
mm I-OSE_Labeled_AE
3 I-OSE_Labeled_AE
were O
associated O
with O
an O
increased O
incidence O
of O
treated O
and O
serious O
infections B-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
. O

Neutropenia B-OSE_Labeled_AE
In O
the O
controlled O
clinical O
trials O
, O
confirmed O
decreases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
ANC I-OSE_Labeled_AE
below O
1000 O
cells/mm O
3 O
occurred O
in O
0.07 O
% O
of O
patients O
for O
the O
5 O
mg O
twice O
daily O
and O
10 O
mg O
twice O
daily O
XELJANZ O
groups O
combined O
during O
the O
first O
3 O
months O
of O
exposure O
. O

There O
were O
no O
confirmed O
decreases B-NonOSE_AE
in I-NonOSE_AE
ANC I-NonOSE_AE
below O
500 O
cells/mm O
3 O
observed O
in O
any O
treatment O
group O
. O

There O
was O
no O
clear O
relationship O
between O
neutropenia B-NonOSE_AE
and O
the O
occurrence O
of O
serious O
infections B-NonOSE_AE
. O

In O
the O
long-term O
safety O
population O
, O
the O
pattern O
and O
incidence O
of O
confirmed O
decreases B-NonOSE_AE
in I-NonOSE_AE
ANC I-NonOSE_AE
remained O
consistent O
with O
what O
was O
seen O
in O
the O
controlled O
clinical O
trials O
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
. O

Liver O
Enzyme O
Elevations O
Confirmed O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
liver I-OSE_Labeled_AE
enzymes I-OSE_Labeled_AE
greater O
than O
3 O
times O
the O
upper O
limit O
of O
normal O
( O
3* O
ULN O
) O
were O
observed O
in O
patients O
treated O
with O
XELJANZ O
. O

In O
patients O
experiencing O
liver B-OSE_Labeled_AE
enzyme I-OSE_Labeled_AE
elevation I-OSE_Labeled_AE
, O
modification O
of O
treatment O
regimen O
, O
such O
as O
reduction O
in O
the O
dose O
of O
concomitant O
DMARD O
, O
interruption O
of O
XELJANZ O
, O
or O
reduction O
in O
XELJANZ O
dose O
, O
resulted O
in O
decrease B-NonOSE_AE
or O
normalization O
of O
liver I-NonOSE_AE
enzymes I-NonOSE_AE
. O

In O
the O
controlled O
monotherapy O
trials O
( O
0-3 O
months O
) O
, O
no O
differences O
in O
the O
incidence O
of O
ALT B-NonOSE_AE
or O
AST O
elevations I-NonOSE_AE
were O
observed O
between O
the O
placebo O
, O
and O
XELJANZ O
5 O
mg O
, O
and O
10 O
mg O
twice O
daily O
groups O
. O

In O
the O
controlled O
background O
DMARD O
trials O
( O
0-3 O
months O
) O
, O
ALT B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
greater O
than O
3* O
ULN O
were O
observed O
in O
1.0 O
% O
, O
1.3 O
% O
and O
1.2 O
% O
of O
patients O
receiving O
placebo O
, O
5 O
mg O
, O
and O
10 O
mg O
twice O
daily O
, O
respectively O
. O

In O
these O
trials O
, O
AST B-NonOSE_AE
elevations I-NonOSE_AE
greater O
than O
3* O
ULN O
were O
observed O
in O
0.6 O
% O
, O
0.5 O
% O
and O
0.4 O
% O
of O
patients O
receiving O
placebo O
, O
5 O
mg O
, O
and O
10 O
mg O
twice O
daily O
, O
respectively O
. O

One O
case O
of O
drug B-OSE_Labeled_AE
- I-OSE_Labeled_AE
induced I-OSE_Labeled_AE
liver I-OSE_Labeled_AE
injury I-OSE_Labeled_AE
was O
reported O
in O
a O
patient O
treated O
with O
XELJANZ O
10 O
mg O
twice O
daily O
for O
approximately O
2.5 O
months O
. O

The O
patient O
developed O
symptomatic O
elevations B-OSE_Labeled_AE
of O
AST I-OSE_Labeled_AE
and O
ALT O
greater O
than O
3* O
ULN O
and O
bilirubin B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
greater O
than O
2* O
ULN O
, O
which O
required O
hospitalizations O
and O
a O
liver O
biopsy O
. O

Lipid O
Elevations O
In O
the O
controlled O
clinical O
trials O
, O
dose-related O
elevations B-OSE_Labeled_AE
in I-OSE_Labeled_AE
lipid I-OSE_Labeled_AE
parameters O
( O
total O
cholesterol O
, O
LDL O
cholesterol O
, O
HDL O
cholesterol O
, O
triglycerides O
) O
were O
observed O
at O
one O
month O
of O
exposure O
and O
remained O
stable O
thereafter O
. O

Changes O
in O
lipid O
parameters O
during O
the O
first O
3 O
months O
of O
exposure O
in O
the O
controlled O
clinical O
trials O
are O
summarized O
below O
: O
* O
Mean O
LDL B-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
by O
15 O
% O
in O
the O
XELJANZ O
5 O
mg O
twice O
daily O
arm O
and O
19 O
% O
in O
the O
XELJANZ O
10 O
mg O
twice O
daily O
arm O
. O

* O
Mean O
HDL B-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
by O
10 O
% O
in O
the O
XELJANZ O
5 O
mg O
twice O
daily O
arm O
and O
12 O
% O
in O
the O
XELJANZ O
10 O
mg O
twice O
daily O
arm O
. O

* O
Mean O
LDL/HDL O
ratios O
were O
essentially O
unchanged O
in O
XELJANZ-treated O
patients O
. O

In O
a O
controlled O
clinical O
trial O
, O
elevations B-NonOSE_AE
in I-NonOSE_AE
LDL I-NonOSE_AE
cholesterol I-NonOSE_AE
and O
ApoB O
decreased O
to O
pretreatment O
levels O
in O
response O
to O
statin O
therapy O
. O

In O
the O
long-term O
safety O
population O
, O
elevations B-OSE_Labeled_AE
in I-OSE_Labeled_AE
lipid I-OSE_Labeled_AE
parameters O
remained O
consistent O
with O
what O
was O
seen O
in O
the O
controlled O
clinical O
trials O
. O

Serum O
Creatinine O
Elevations O
In O
the O
controlled O
clinical O
trials O
, O
dose-related O
elevations B-OSE_Labeled_AE
in O
serum I-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
were O
observed O
with O
XELJANZ O
treatment O
. O

The O
mean O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
was O
< O
0.1 O
mg/dL O
in O
the O
12-month O
pooled O
safety O
analysis O
; O
however O
with O
increasing O
duration O
of O
exposure O
in O
the O
long-term O
extensions O
, O
up O
to O
2 O
% O
of O
patients O
were O
discontinued O
from O
XELJANZ O
treatment O
due O
to O
the O
protocol-specified O
discontinuation O
criterion O
of O
an O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
by O
more O
than O
50 O
% O
of O
baseline O
. O

The O
clinical O
significance O
of O
the O
observed O
serum B-NonOSE_AE
creatinine I-NonOSE_AE
elevations I-NonOSE_AE
is O
unknown O
. O

Other O
Adverse O
Reactions O
Adverse O
reactions O
occurring O
in O
2 O
% O
or O
more O
of O
patients O
on O
5 O
mg O
twice O
daily O
or O
10 O
mg O
twice O
daily O
XELJANZ O
and O
at O
least O
1 O
% O
greater O
than O
that O
observed O
in O
patients O
on O
placebo O
with O
or O
without O
DMARD O
are O
summarized O
in O
Table O
4 O
. O

Table O
4 O
: O
Adverse O
Reactions O
Occurring O
in O
at O
Least O
2 O
% O
or O
More O
of O
Patients O
on O
5 O
or O
10 O
mg O
Twice O
Daily O
XELJANZ O
With O
or O
Without O
DMARD O
( O
0-3 O
months O
) O
and O
at O
Least O
1 O
% O
Greater O
Than O
That O
Observed O
in O
Patients O
on O
Placebo O
XELJANZ5 O
mg O
Twice O
Daily O
XELJANZ10 O
mg O
Twice O
Daily O
Placebo O
Preferred O
Term O
N O
= O
1336 O
( O
% O
) O
N O
= O
1349 O
( O
% O
) O
N O
= O
809 O
( O
% O
) O
N O
reflects O
randomized O
and O
treated O
patients O
from O
the O
seven O
clinical O
trials O
Diarrhea B-OSE_Labeled_AE
4.0 O
2.9 O
2.3 O
Nasopharyngitis B-OSE_Labeled_AE
3.8 O
2.8 O
2.8 O
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
4.5 O
3.8 O
3.3 O
Headache B-OSE_Labeled_AE
4.3 O
3.4 O
2.1 O
Hypertension B-OSE_Labeled_AE
1.6 O
2.3 O
1.1 O
Other O
adverse O
reactions O
occurring O
in O
controlled O
and O
open-label O
extension O
studies O
included O
: O
Blood B-NonOSE_AE
and O
lymphatic O
system O
disorders I-NonOSE_AE
: O
Anemia B-OSE_Labeled_AE
Infections B-NonOSE_AE
and I-NonOSE_AE
infestations I-NonOSE_AE
: O
Diverticulitis B-OSE_Labeled_AE
Metabolism B-NonOSE_AE
and I-NonOSE_AE
nutrition I-NonOSE_AE
disorders I-NonOSE_AE
: O
Dehydration B-OSE_Labeled_AE
Psychiatric B-NonOSE_AE
disorders I-NonOSE_AE
: O
Insomnia B-OSE_Labeled_AE
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
Paresthesia B-OSE_Labeled_AE
Respiratory B-NonOSE_AE
, O
thoracic O
and O
mediastinal O
disorders I-NonOSE_AE
: O
Dyspnea B-OSE_Labeled_AE
, O
cough B-OSE_Labeled_AE
, O
sinus B-OSE_Labeled_AE
congestion I-OSE_Labeled_AE
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
: O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
dyspepsia B-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
, O
gastritis B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
Hepatobiliary B-NonOSE_AE
disorders I-NonOSE_AE
: O
Hepatic B-OSE_Labeled_AE
steatosis I-OSE_Labeled_AE
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
: O
Rash B-OSE_Labeled_AE
, O
erythema B-OSE_Labeled_AE
, O
pruritus B-OSE_Labeled_AE
Musculoskeletal B-NonOSE_AE
, I-NonOSE_AE
connective I-NonOSE_AE
tissue I-NonOSE_AE
and I-NonOSE_AE
bone I-NonOSE_AE
disorders I-NonOSE_AE
: O
Musculoskeletal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
arthralgia B-OSE_Labeled_AE
, O
tendonitis B-OSE_Labeled_AE
, O
joint B-OSE_Labeled_AE
swelling I-OSE_Labeled_AE
Neoplasms B-NonOSE_AE
benign I-NonOSE_AE
, I-NonOSE_AE
malignant I-NonOSE_AE
and I-NonOSE_AE
unspecified I-NonOSE_AE
( I-NonOSE_AE
including I-NonOSE_AE
cysts I-NonOSE_AE
and I-NonOSE_AE
polyps I-NonOSE_AE
) O
: O
Non B-OSE_Labeled_AE
- I-OSE_Labeled_AE
melanoma I-OSE_Labeled_AE
skin I-OSE_Labeled_AE
cancers I-OSE_Labeled_AE
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
conditions I-NonOSE_AE
: O
Pyrexia B-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
Clinical O
Experience O
in O
Methotrexate-Naive O
Patients O
Study O
VI O
was O
an O
active-controlled O
clinical O
trial O
in O
methotrexate-naive O
patients O
[ O
see O
Clinical O
Studies O
( O
14 O
) O
] O
. O

The O
safety O
experience O
in O
these O
patients O
was O
consistent O
with O
Studies O
I-V O
. O

